Validation of a De Novo Health Economic Model for Finerenone in Heart Failure with Left Ventricular Ejection Fraction ≥40 [0.03%]
左心室射血分数≥40%的心力衰竭中 finerenone 从头开始的健康经济模型验证研究
Tobiasz Lemański,Kerstin Folkerts,Phil McEwan et al.
Tobiasz Lemański et al.
This study aimed to validate the health economic model for finerenone in the treatment of patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≥40% in the United Kingdom. A Markov model informed by the pivotal FIN...
Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development Strategies [0.03%]
论药品开发中未被满足的医疗需求：对监管和临床研发策略的影响及评估
Carla Domingo-Esteban,Inka Heikkinen,Nanco Hefting
Carla Domingo-Esteban
Unmet need is a core component of many Health Technology Assessment (HTA) processes at EU and national level. Most visibly, it is a core selection criterion for Joint Scientific Consultations (JSC) and Joint Clinical Assessment (JCA) for me...
Can We Trust PAICs in Rare Diseases? Methodological Challenges and Limitations [0.03%]
罕见病中PAICs的可靠性如何？方法学挑战与局限性分析
Mikolaj Parkitny,Samuel Aballéa,Piotr Wojciechowski et al.
Mikolaj Parkitny et al.
Population-adjusted indirect comparisons (PAICs), including Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison, are increasingly used to inform health technology assessments. These methods offer a pragmatic approach to...
Structural Enablers of Rare Disease Treatment Coverage in Latin America and the Caribbean: Lessons from Emicizumab [0.03%]
拉美和加勒比地区罕见病治疗保障的结构性驱动因素——emicizumab的启示
Daniela Sugg Herrera,Dino Sepúlveda Viveros,Moisés Russo Namias et al.
Daniela Sugg Herrera et al.
We examine how structural characteristics of health systems in Latin America and the Caribbean (LAC) shape access to innovative therapies, using emicizumab for hemophilia A as a case study. Although the therapy is available in the region, a...
Updated Conversion Table for the Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE" [0.03%]
“MARIE”多标准定性价值定价框架的更新换算表
Akina Takami,Ataru Igarashi
Akina Takami
Background: Value-based pricing has the potential to contribute to the appropriate allocation of healthcare expenditures. We developed the "MARIE", a qualitative scheme that evaluates broad value elements without requiring a comparator to e...
Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies [0.03%]
肺动脉高压和癌症：揭示流行病学、临床路径和治疗策略的平行关系
Karim Ei-Kersh,Nadine Zawadzki,Catelyn Coyle et al.
Karim Ei-Kersh et al.
Pulmonary arterial hypertension (PAH) and cancer share high mortality and complex prognoses. Due to PAH's rarity, these parallels may be underrecognized by healthcare stakeholders. This study explored similarities between PAH and cancer acr...
Adopting a Societal Perspective in Health-Economic Evaluation: Analysis of Nine HTA Methodological Guidelines on How to Integrate Societal Costs [0.03%]
从社会视角进行卫生经济学评价：九个HTA方法学指南中将社会成本整合的分析方法评估
Chloé Gervès-Pinquié,Hortense Nanoux,Sarah Akarkoub et al.
Chloé Gervès-Pinquié et al.
Objective: The perspective applied in Health Technology Assessment (HTA) has recently been presented as a central methodological debate in HTA. Beyond expected effects on patients' health and quality of life, health techn...
Evaluating [18F]-DCFPyL for Detecting Prostate Cancer Recurrence: A Cost-Consequence Comparison with Alternative PET Radiotracers in Spain [0.03%]
[18F]-DCFPyL在西班牙检测前列腺癌复发中的经济学评价：与替代PET放射示踪剂的经济后果对比研究
Tiago Matos,Mrunmayee Godbole,Rithvik Badinedi et al.
Tiago Matos et al.
Introduction: [18F]-DCFPyL (Piflufolastat [18F]) is a prostate-specific membrane antigen (PSMA)-targeted position emission tomography (PET) radiotracer for detecting the biochemical recurrence (BCR) of prostate cancer (PCa). This study eval...
A Cost-Effectiveness Analysis of the Sentio Bone Conduction Hearing Implant System in the Australian Healthcare Setting [0.03%]
Sentio骨传导听觉植入系统在澳大利亚医疗体系中的成本效益分析
Magnus Värendh,Ida Haggren,Helén Lagerkvist et al.
Magnus Värendh et al.
Bone conduction hearing implant systems (BCHIs) are established treatments for patients with conductive or mixed hearing loss or single-sided deafness when conventional hearing aids are unsuitable. This study evaluated the cost-effectivenes...
Tosin Adeyemo,Tim Wilsdon,Christina Vandorou et al.
Tosin Adeyemo et al.
European citizens made it clear in 2024 that healthcare should be the EU's top priority for shaping the future of Europe. This sentiment reflects the escalating health challenges facing the region, driven by ageing populations, rising chron...